Oncology is one island where biotech investment continues in the sea of shrinking biopharma. As expected, the current environment is also conducive to oncology biotech companies being lost to mergers and acquisitions. Sadly, these carefully crafted and nurtured brands will be lost for ever!
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label BRAF. Show all posts
Showing posts with label BRAF. Show all posts
Saturday, December 31, 2011
Wednesday, June 8, 2011
The Four Percent Lung Cancer Solution
A small group of lung cancer patients, who carry EML4-ALK marker in their tumor genome, can now look forward to a cancer-free future, thanks to a new drug crizotinib being developed by Pfizer. This group of patients are generally nonsmokers or had given up smoking long ago, but still have the misfortune of coming down with lung cancer.
Subscribe to:
Posts (Atom)